CDK4/6 blockade provides an alternative approach for treatment of mismatch-repair deficient tumors
Inken Salewski, Julia Henne, Leonie Engster, Paula Krone, Björn Schneider, Caterina Redwanz, Heiko Lemcke, Larissa Henze, Christian Junghanß, Claudia Maletzki
Abstract
. The immune-modulatory potential of abemaciclib renders this compound ideal for dMMR patients not eligible for ICI treatment.
Topics & Concepts
BlockadeMedicineCancer researchOncologyInternal medicineReceptorAdvanced Breast Cancer TherapiesCancer-related cognitive impairment studiesBreast Cancer Treatment Studies